ANIP
ANI Pharmaceuticals Inc
NASDAQ: ANIP · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$77.97
-0.68% today
Updated 2026-04-29
Market cap
$1.77B
P/E ratio
23.48
P/S ratio
2.01x
EPS (TTM)
$3.32
Dividend yield
—
52W range
$57 – $100
Volume
0.4M
WallStSmart proprietary scores
55
out of 100
Grade: C+
Hold
Investment rating
6.7
Growth
B5.3
Quality
C+6.5
Profitability
B5.7
Valuation
C+3/9
Piotroski F-Score
Weak
1.5
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →201 stocks currently score above 75
Price targets
Analyst target
$110.62
+41.88%
12-Month target
$61.55
-21.06%
Intrinsic (DCF)
—
Margin of safety
—
3 Strong Buy4 Buy1 Hold0 Sell0 Strong Sell
Price chart
X-Ray snapshot
Strengths
+ Free cash flow $6.51M — positive
+ Revenue growth 29.60% QoQ
Risks
- Piotroski 3/9 — weak financial health
- Altman Z 1.49 — distress zone
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $316.38M | $486.82M | $614.38M | $883.37M | $883.37M |
| Net income | $-47.90M | $18.78M | $-18.52M | $78.34M | $27.49M |
| EPS | — | — | — | — | $3.32 |
| Free cash flow | $-47.66M | $100.45M | $47.06M | $171.39M | $6.51M |
| Profit margin | -15.14% | 3.86% | -3.01% | 8.87% | 8.87% |
Peer comparison
Smart narrative
ANI Pharmaceuticals Inc trades at $77.97. representing a P/E of 23.48x trailing earnings. Our Smart Value Score of 55/100 indicates the stock is fair. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 1.49, it sits in the distress. TTM revenue stands at $883.37M. with profit margins at 8.87%.
Frequently asked questions
What is ANI Pharmaceuticals Inc's stock price?
ANI Pharmaceuticals Inc (ANIP) trades at $77.97.
Is ANI Pharmaceuticals Inc overvalued?
Smart Value Score 55/100 (Grade C+, Hold).
What is the price target of ANI Pharmaceuticals Inc (ANIP)?
The analyst target price is $110.62, representing +41.9% upside from the current price of $77.97.
What is ANI Pharmaceuticals Inc's revenue?
TTM revenue is $883.37M.
Piotroski F-Score?
3/9 — weak financial health.
Altman Z-Score?
1.49 — distress.
Company info
SectorHEALTHCARE
IndustryDRUG MANUFACTURERS - SPECIALTY & GENERIC
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio2.01x
ROE16.20%
Beta0.44
50D MA$76.43
200D MA$82.47
Shares out0.02B
Float0.02B
Short ratio—
Avg volume0.4M
Performance
1 week—
1 month—
3 months—
YTD—
1 year—
3 years—
5 years—